Lead Product(s): Ent001
Therapeutic Area: Endocrinology Product Name: Ent001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Sofinnova Partners
Deal Size: $33.1 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2020
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.